Neogen (NEOG) Non-Current Deferred Tax Liability (2011 - 2026)
Neogen's (NEOG) quarterly Non-Current Deferred Tax Liability came in at $269.2 million in Q1 2026, down 10.58% year-on-year from $301.1 million in Q1 2025, and down 1.73% quarter-over-quarter from $273.9 million in Q4 2025.
Neogen (NEOG) Non-Current Deferred Tax Liability (2011 - 2026) Analysis & Trends
Neogen's Non-Current Deferred Tax Liability history runs 16 years deep, the most recent figure standing at $269.2 million for Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 10.58% year-over-year to $269.2 million in Q1 2026; TTM through Feb 2026 was $269.2 million, a 10.58% decrease from a year earlier, with the FY2025 full-year figure at $280.9 million, down 14.02% from the prior year.
- Non-Current Deferred Tax Liability declined to $269.2 million in Q1 2026 per NEOG's latest filing, from $273.9 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $364.3 million in Q4 2022 and bottomed at $15.9 million in Q3 2022.
- The 5-year median for Non-Current Deferred Tax Liability is $302.4 million (2024), against an average of $267.5 million.
- Across the five-year window, Non-Current Deferred Tax Liability declined 26.93% in 2022 and surged 2124.54% in 2023, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $364.3 million in 2022, then declined by 2.54% to $355.0 million in 2023, then retreated by 14.82% to $302.4 million in 2024, then slipped by 9.41% to $273.9 million in 2025, then retreated by 1.73% to $269.2 million in 2026.
- Per Business Quant, the three latest NEOG Non-Current Deferred Tax Liability figures stand at $269.2 million (Q1 2026), $273.9 million (Q4 2025), and $277.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.32 Bn | 174.03 Bn | 6.27 Bn |
| 2 | Stryker | 128.59 Bn | 125.71 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.77 Bn | 66.32 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.46 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.44 Bn | 26.15 Bn | 1.98 Bn |
| 7 | Dexcom | 28.41 Bn | 27.29 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.77 Bn | 26.20 Bn | - |
| 9 | Koninklijke Philips | 25.24 Bn | 22.11 Bn | 2.07 Bn |
| 10 | Neogen | 2.07 Bn | 1.91 Bn | 99.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 269.20 Mn |
| Feb 28, 2026 | 269.20 Mn |
| Nov 30, 2025 | 273.95 Mn |
| Nov 30, 2025 | 273.95 Mn |
| Aug 31, 2025 | 277.25 Mn |
| Aug 31, 2025 | 277.25 Mn |
| May 31, 2025 | 280.90 Mn |
| May 31, 2025 | 280.90 Mn |
| Feb 28, 2025 | 301.05 Mn |
| Feb 28, 2025 | 301.05 Mn |
| Nov 30, 2024 | 302.41 Mn |
| Nov 30, 2024 | 302.41 Mn |
| Aug 31, 2024 | 317.57 Mn |
| Aug 31, 2024 | 317.57 Mn |
| May 31, 2024 | 326.72 Mn |
| May 31, 2024 | 326.72 Mn |
| Feb 29, 2024 | 353.85 Mn |
| Feb 29, 2024 | 353.85 Mn |
| Nov 30, 2023 | 355.01 Mn |
| Nov 30, 2023 | 355.01 Mn |